1:59 am Amgen reports new detailed data from three Phase 3 pivotal studies show investigational cholesterol-lowering medicine Evolocumab significantly reduced LDL cholesterol By 55-66%

1:59 am Amgen reports new detailed data from three Phase 3 pivotal studies show investigational cholesterol-lowering medicine Evolocumab significantly reduced LDL cholesterol By 55-66%

more

View todays social media effects on AMGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Amgen is hiring next, click here to view

Share this post